نبذة مختصرة : The Present studies is Liposomes have been used to target drug to specific organs, delay the loss of rapidly cleared, drugs, enhances therapeutic potency and offer a host of the other advantages. Doxorubicin hydrochloride is one of the most commonly used cytotoxic anthracycline antibiotics used in cancer chemotherapy and has been shown to have activity against a wide variety of neoplasms. Conventional compositions of doxorubicin hydrochloride are available as freeze-dried product (or) as a solution of doxorubicin hydrochloride in water. Both these products have been associated with a number of toxicities when administered intravenously. Severe myelosupression, nausea, vomiting, alopecia, mucosistis & cardio toxicity, limits the use of Doxorubicin Hcl. It also causes extravasations & necrosis at the site of injection. To overcome these problems, an alternative approach is needed. In the study doxorubicin Hcl liposomes are formulated using various biolipids and Stabilizers (Positive and Negative) to check effect of drug loading and particle size. Several approaches has taken in an effort to increase the circulation time of liposome by coating the liposomal surface with a hydrophilic polymer such as polyethylene glycol (PEG) to prevent adsorption of various blood plasma proteins to the liposome surface. These liposomes appeared to reduce some of the toxic effects caused by the release of their contents, but have new toxic effects appeared like skin toxicity generally known as “Hand-Foot Syndrome” and the presence of large molecules (PEG) on the liposomal surface may reduce the interaction of liposomal with cells & hinder entry of liposomes in to tumor tissue. Thus, these remains a need for stable, long circulating liposomes that do not cause such deleterious effects such as the “Hand-Foot Syndrome” as well as methods of manufacturing such liposomes & composition based on them. The present formulation meets this need, and testing the effect of stabilizers on particle size analysis, percent free drug, ...
No Comments.